Lawn, Stephen D; Wood, Robin; (2011) Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. The Journal of infectious diseases, 204 Su (suppl). S1159 – S1167. ISSN 0022 – 1899 DOI: https://doi.org/10.1093/infdis/jir411

Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/19154/

DOI: https://doi.org/10.1093/infdis/jir411

Usage Guidelines:

Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by-nc-nd/2.5/
Tuberculosis in Antiretroviral Treatment Services in Resource-Limited Settings: Addressing the Challenges of Screening and Diagnosis

Stephen D. Lawn1,2 and Robin Wood1

1Desmond Tutu HIV Centre, Institute for Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa; and 2Department of Clinical Research, Faculty of Infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, London, United Kingdom

The high burden of tuberculosis (TB) among patients accessing antiretroviral treatment (ART) services in resource-limited settings is a major cause of morbidity and mortality and is associated with nosocomial transmission risk. These risks are greatly compounded by multidrug-resistant disease. Screening and diagnosis of TB in this clinical setting is difficult. However, progress has been made in defining a high-sensitivity, standardized symptom screening tool that assesses a combination of symptoms, rather than relying on report of cough alone. Moreover, newly emerging diagnostic tools show great promise in providing more rapid diagnosis of TB, which is predominantly sputum smear-negative. These include culture-based systems, simplified versions of nucleic acid amplification tests (such as the Xpert MTB/RIF assay), and detection of lipoarabinomannan antigen in urine. In addition, new molecular diagnostics now permit rapid detection of drug resistance. Further development and implementation of these tools is vital to permit rapid and effective screening for TB in ART services, which is an essential component of patient care.

The geographical intersection of the HIV pandemic with the existing global tuberculosis (TB) epidemic has led to high rates of HIV-associated TB and related mortality over the past 25 years [1]. During 2008, there were an estimated 1.4 million incident cases of HIV-associated TB worldwide, which accounted for 25% (0.5 million) of global deaths from HIV infection and AIDS [2]. Sub-Saharan Africa bears the brunt of this epidemic, accounting for 4 of 5 cases of HIV-associated TB worldwide [2]. TB incidence rates have increased 3–5-fold in many African countries with a high prevalence of HIV infection, and in the worst affected countries of South Africa and Swaziland, ~1% of the national population develops TB each year [2]. The region with the second highest burden is southern and Southeast Asia, with 13% of the global caseload.

Extraordinary progress has been made in scaling up access to antiretroviral therapy (ART) in low- and middle-income countries (reaching 5.3 million persons by the end of 2009) [3]. A majority of these persons (3.9 million) were in sub-Saharan Africa. Scale-up of ART in settings with a high burden of TB is associated with a number of opportunities and challenges. ART is a crucial component of case management of HIV-associated TB [4], reducing mortality risk by 64%–95% [5] and halving recurrence rates [6]. In addition, ART has an important role in the prevention of HIV-associated TB, reducing risk in treated cohorts by a mean of 67% (95% confidence interval [CI], 61%–73%) [7]. Furthermore, aggressive ART scale-up could potentially play a key role in the control of this epidemic [8].

However, high rates of TB also present many challenges for ART services: TB is a major cause of morbidity and mortality, concurrent TB treatment and ART is complex [9, 10], and TB is associated with a substantial
risk of nosocomial transmission [11]. These challenges are amplified greatly by the major difficulties of screening and diagnosing TB in this group of patients. This may, in part, explain why only 4.1% of patients living with HIV infection worldwide were estimated to have been screened for TB during 2008 [2].

In this article, we describe the burden and impact of TB on adults accessing ART programs in resource-constrained settings. We highlight the importance of effective TB screening and reliable diagnosis and review the range of conventional and novel TB diagnostic tools available for use in this context. A majority of the data reported are from sub-Saharan Africa. However, the principles outlined are relevant to other resource-constrained settings.

**HIV PROGRESSION AND TB RISK**

HIV infection has a critical impact on the host cell-mediated response to *Mycobacterium tuberculosis* [12]. The risk of TB increases 2–3-fold within the first 2 years of HIV seroconversion [13] and continues to increase as CD4 cell counts decrease (Figure 1) [14, 16]. HIV-infected individuals with *M. tuberculosis* infection have a mean annual risk of developing TB of ~10% per year [17]; however, this risk is highly dependent on the degree of immunodeficiency, the prevailing socioeconomic conditions, and ongoing risk of TB exposure. Rates of HIV-associated TB approach 30% per year among persons with the lowest CD4 cell counts who live in Cape Town, South Africa (Figure 1) [14].

Reported TB incidence rates among patients with advanced HIV-associated immunodeficiency, however, belie a conceptual difficulty with regard to the definition of TB disease. The traditional concept of HIV-infected patients being classified as either having active TB or not having active TB has been questioned [18], and the existing paradigm that distinguishes latent TB infection from active TB disease as distinct binary states is thought to be overly simplistic. Our understanding of the host-pathogen dynamics of *M. tuberculosis* infection has fundamentally altered in recent years. It is now thought to be likely that a spectrum of states exists, with different degrees of immune control and mycobacterial load [19, 20] and that HIV infection profoundly shifts this spectrum in favor of bacillary replication (Figure 2) [18].

This concept has important consequences for our understanding of the burden of TB in ART programs. Because this patient population has advanced immunodeficiency, many patients will have prevalent symptomatic TB disease and many others may have subclinical, actively replicating infection that may fall near the limits of detection of TB diagnostic assays.

**CLINICO-PATHOLOGICAL CHARACTERISTICS OF HIV-ASSOCIATED TB**

The challenge of TB diagnosis in patients in ART programs relates to the blurring of active disease and latent infection and to the impact of HIV on the clinico-pathological features of TB. The features of TB in HIV-1–infected individuals with well-preserved CD4 cell counts are similar to those of individuals with TB but no HIV-1 coinfection. Progressive immunodeficiency, however, is associated with an increasing frequency of miliary and
disseminated forms of disease [21, 22], and occult disseminated TB has also been a frequent finding in postmortem studies involving persons who died with HIV infection or AIDS in sub-Saharan Africa [23, 24]. Evidence of the impaired tissue inflammatory response to infection is seen in the radiographic appearances of pulmonary TB, with reduced consolidation, fibrosis, and cavitation [25, 26]. Lack of cavitation in turn results in low numbers of bacilli in sputum specimens; thus, results of sputum smear microscopy for acid-fast bacilli are frequently negative [22, 27].

**BURDEN OF TB IN ART PROGRAMS**

**TB Referrals to ART Programs**

HIV-infected patients typically present to health services in resource-limited settings with advanced immunodeficiency and opportunistic infections [28], with TB being one of the most common presentations [29]. The proportion of patients with TB who undergo HIV testing has increased substantially in recent years [2], being catalyzed by implementation of the provider-initiated HIV testing and counseling strategy in TB programs. As a result, the proportion of patients referred to ART programs who have a known TB diagnosis has increased substantially in some settings; for example, this proportion increased from 16% to 35% of referrals to a South African ART service over a 6-year period [30].

**Prevalent Undiagnosed TB at Baseline**

In addition to patients with known TB, there is a large burden of undiagnosed TB in other patients. The proportion detected is likely to vary greatly depending on the prevailing TB burden, the degree of immunodeficiency, and the rigor with which patients are screened. The prevalence of TB is established most accurately when all patients are screened for TB regardless of the presence or absence of symptoms and when high-sensitivity investigations, such as automated liquid culture, are used [31, 32]. In 2 studies involving South African cohorts, patients had median CD4 cell counts of ~100 cells/µL, and pulmonary TB was diagnosed in 19% [33] and 25% [34] of patients when sputum samples from all patients were examined using automated liquid culture.

Data from these 2 South African studies are likely to represent the upper end of the range of TB prevalence, but similar studies in ART programs in countries with less severe TB epidemics are lacking. However, patients attending HIV clinics or voluntary counseling and testing services in Southeast Asia have been reported to have a TB prevalence of 6%–15% [35–37]. A systematic review of the yield of TB screening in HIV-infected patients attending ART and medical clinics in resource-limited settings found a median prevalence of 8.2% (range, 1%–25%), detected using a wide range of screening strategies [31]. The yield was strongly associated with TB prevalence in the country and the screening strategy.

**Incident TB During ART**

TB risk persists during ART. Incidence rates are particularly high during the first few months of ART, although this is strongly dependent on the intensity of screening at baseline [38]. A proportion of patients with TB at baseline are either asymptomatic or have minimal symptoms and are not clinically recognized until immune recovery triggers the development of symptoms during early ART (so-called “unmasking TB”) [39]. Under routine program conditions in a Cape Town ART service, it was estimated that ~40% of TB cases presenting during the first 4 months of ART were caused by unmasking TB [15]. Consistent with this finding, implementation of an intensive pretreatment screening strategy using liquid culture of induced sputum samples approximately halved the TB incidence rate during this period [38].

TB incidence rates diminish rapidly with ongoing immune recovery during ART. Data from cohort studies in both high-income and resource-limited settings report TB risk reductions of 54%–92% in adjusted analyses [5] and a pooled summary estimate of a 67% reduction (95% CI, 61%–73%) [7]. The reduction in TB incidence rates is time-dependent, with ongoing reductions during the first 2–3 years of treatment [29, 40–43], reflecting the rate of ART-induced immune recovery [15]. TB risk is strongly associated with the current CD4 cell count; an increase in CD4 cell count from <100 cells/µL to >500 cells/µL is associated with a 10-fold reduction in TB risk [15] (Figure 1). Data are lacking on how TB prevalence changes over time during ART, although it is likely that the highest yield of new cases would be detected by screening persons with poor CD4 cell count recovery.

**POTENTIAL BENEFITS OF TB SCREENING AND DIAGNOSIS**

There is a very strong rationale for screening and rapid TB diagnosis among patients accessing ART services (Table 1). Efficient baseline screening is associated with a substantial reduction in the risk of incident TB and associated morbidity during the initial months of ART [38]. TB is the most common reported cause of death in ART programs and frequently remains undiagnosed [28]. Postmortem data are few; however, in a series of 25 patients receiving ART who died after hospital admission in Johannesburg, South Africa, disseminated mycobacterial disease was found in 19 [44]. Similarly, in another South African hospital, approximately half the deaths among HIV-infected adults were associated with culture-confirmed TB [45]. Studies are needed to determine whether rapid screening and diagnosis of TB in this patient group improves survival. In the absence of effective diagnostic tools, an alternative approach may be to provide empirical TB treatment to persons at highest risk of TB and associated mortality [46]. Studies exploring such a strategy are needed, and one is being planned by the AIDS
Clinical Trials Group (ACTG5274 REMEMBER trial; Mina Hosseinipour, personal communication).

TB in patients accessing ART services presents a serious infection-control hazard [11]. This hazard is likely to be highest among newly enrolling ART-naive patients who have a high prevalence of undiagnosed disease and who often spend considerable time with groups of peers preparing for treatment in over-crowded facilities. Multidrug-resistant (MDR) TB presents a particularly important threat [11, 47]. Nosocomial transmission was thought to be a key factor in the 2006 outbreak of extensively drug-resistant TB (XDR-TB) among patients accessing ART from a district hospital in rural KwaZulu Natal, South Africa [48]. Screening and rapid diagnosis leading to early commencement of TB treatment are central to reducing the period of infectiousness and transmission risk.

In a small minority of patients, the clinical presentation of unmasking TB during the initial months of ART may be severe, with immune reconstitution disease causing considerable immunopathology and clinical compromise [39, 49, 50]. In such cases, effective screening and early TB diagnosis and initiation of TB treatment may diminish the risk of these severe forms of disease.

World Health Organization (WHO) guidelines recommend that TB should be diagnosed and treated before initiation of ART [51]. Difficulties in diagnosing TB may therefore contribute to delays in initiation of ART, and this may be associated with considerable mortality risk [52, 53]. Thus, rapid and effective TB screening and diagnostic strategies are needed to permit efficient commencement of TB treatment and ART. Similarly, implementation of isoniazid preventive therapy in patients with advanced immunodeficiency has been greatly undermined by the difficulties of reliably excluding active TB. More reliable screening methods may facilitate greater uptake in this patient group in whom there is some evidence of an additive preventive effect when combined with ART [7].

**SCRENNING AND DIAGNOSTIC METHODS**

**Symptom Screening**

The WHO previously recommended a cough duration of 2–3 weeks as a symptom screen for TB [51, 54]. This is now recognized as inadequate for HIV-associated TB, with the sensitivity frequently being found to be < 50% in this patient group [32, 52, 53]. Screening tools that combine multiple symptoms have much higher sensitivity, albeit with low specificity. A meta-analysis of ~10 000 HIV-infected patients actively screened for TB was conducted to identify an optimum symptom screening algorithm [55]. The optimum algorithm identified patients with at least 1 of 4 common symptoms (current cough, night sweats, weight loss, or fever) with a sensitivity of 79% and a specificity of 50%. These values are very similar to those found in TB screening studies in 2 ART services in South Africa [33, 34]. This new screening tool has been included in the WHO 2010 guidelines on intensified case finding and isoniazid preventive therapy [56] and represents an important step toward more standardized and effective screening. However, in ART programs in which the prevalence of TB is as high as 20%–25%, there is a strong argument for microbiological screening of all patients regardless of the presence or absence of symptoms [31, 33, 34]. However, the overall clinical benefits and associated costs are as yet unknown.

**Sputum Smear Microscopy**

TB diagnosis in resource-limited settings remains heavily reliant on smear microscopy using direct Ziehl–Neelsen staining of sputum. Although this method is highly specific, fast, and relatively inexpensive, it is operator dependent and its use is greatly impaired in the context of HIV infection. A concentration of ~10 000 bacilli per mL of sputum is required for a smear result to be positive; the higher the bacillary concentration is above this threshold, the greater the likelihood of positivity. However, lack of pulmonary cavitation and the resulting low bacillary concentrations in sputum means that sputum microscopy results are usually negative in more than half of patients with HIV-associated TB [27, 32]. Advancing immunodeficiency is associated with increased likelihood of negative smear results; in TB screening studies in South African ART cohorts, >80% of culture-proven TB cases were sputum smear-negative [33, 34].

Although newer technologies are clearly needed, efforts have been made to improve the performance of smear microscopy. In a meta-analysis, sputum processing with bleach or sodium hydroxide and centrifugation was associated with a mean increase in the sensitivity of smear microscopy of 13% [57]. Fluorescence microscopy also increases sensitivity by 10% and retains...
sputum samples analyzed. In a study using automated liquid
monary TB before ART depends substantially on the number of
(MODS) and the nitrate reductase assay.
These include microscopically observed drug susceptibility
test methods were also endorsed by the WHO in 2009 for use
inexpensive, noncommercial culture and drug-susceptibility
diagnosis is unavailable in most resource-limited settings. Thus, alternative
in screening before use of isoniazid preventive therapy [55].

Chest Radiography
The pulmonary radiographic features of TB are markedly af-
fected by HIV coinfection and progressive immunodeficiency
[25, 26]. In addition, the high cost, limited availability in many
settings, and difficulties in interpretation by health care workers
substantially undermine the usefulness of radiography in TB
diagnosis in patients accessing ART services. In a study involving
such patients in Cape Town, the sensitivity of any radiographic
abnormalities consistent with TB was just 68% and the speci-
ficity was 53% [60]. Thus, one-third of patients found to have
sputum culture–positive TB by active screening had completely
normal chest radiograph findings.

However, chest radiology has an important role in diagnosis of
other HIV-related pulmonary diseases, which are also common
in this patient group. When used in combination with symptom
screening algorithms to rule out TB, the addition of radiography
may increase sensitivity further and, therefore, may have use in
screening for TB in this patient population.

Sputum Culture
Automated liquid culture systems are the gold standard for TB
diagnosis and are of great usefulness in this patient population
whom most TB is sputum smear–negative. Liquid culture is
considerably more rapid and has a greater yield than does culture
using solid media. In 2007, these assays were recommended by
the WHO to be used in combination with antigen-based species
confirmation for TB diagnosis and for drug-susceptibility testing
in low- and middle-income countries [61]. However, these
culture systems are expensive and prone to contamination.
Despite its invaluable role observed in TB diagnosis among pa-
tients accessing ART services [33, 34], culture-based diagnosis is
unavailable in most resource-limited settings. Thus, alternative
inexpensive, noncommercial culture and drug-susceptibility
testing methods were also endorsed by the WHO in 2009 for use
as an interim solution in resource-constrained settings [59].
These include microscopically observed drug susceptibility
(MODS) and the nitrate reductase assay.

The sensitivity of culture when screening patients for pul-
monary TB before ART depends substantially on the number of
sputum samples analyzed. In a study using automated liquid
culture of sputum samples from patients starting ART in Cape
Town, 2 samples were collected [34]. The incremental yield of
the second sample was 22% [62], which is similar to the 17%
incremental yield observed a study screening for HIV-associated
TB in Southeast Asia [36]. In the latter study, a third sputum
culture identified 10% of the overall yield of pulmonary TB
cases, indicating that a large majority of cases could be
diagnosed on the basis of culture of 2 samples.

The time to culture positivity is prolonged in this patient
population, reflecting low concentrations of mycobacteria in
sputum. Even with use of automated liquid culture, the mean
time to positivity was >3 weeks in a study in Cape Town [34].
Such delays may contribute to morbidity, mortality, nosocomial
TB transmission, and delayed decision-making regarding ART
initiation. The time to positivity of the MODS assay appears to be
less dependent on sputum smear status, with the median time to
positivity for sputum smear–negative sputum samples reported
to be 7 days, compared with 6 days in sputum smear–positive
samples [63]. The usefulness of MODS should be evaluated in
this patient population.

Testing Nonpulmonary Clinical Samples
A comprehensive evaluation of the additional value of ex-
trapulmonary samples was made in a study in Southeast Asia in
which patients (median CD4 cell count, 281 cells/µL) attending
HIV clinics were intensively screened for TB, with collection of
3 sputum samples together with stool, urine, blood culture, and
(when possible) lymph node aspirates [36]. TB was diagnosed in
14% of patients overall; 86% of these diagnoses were made using
sputum samples, and the additional yield of 14% of diagnoses
were made using culture of nonpulmonary samples. The greatest
yield from nonpulmonary samples was from lymph node aspir-
ate samples, which provided an incremental yield of 6% when
used in addition to liquid culture of 2 sputum samples [36].

Antigen Detection
Although current commercially available serological tests for TB
are of little diagnostic value [64], mycobacterial antigen de-
tection is theoretically more attractive, overcoming many of the
limitations inherent in immune-based assays. A simple, com-
mercially available assay is able to detect lipoarabinomannan
(LAM) excreted in the urine of patients with TB. Although the
sensitivity has been disappointing in HIV-uninfected patients
[65], moderate sensitivity and high specificity has been observed
in HIV-infected patients in South Africa [34, 66, 67].

In each of these studies [34, 66, 67], the sensitivity of the LAM
enzyme-linked immunosorbent assay (ELISA) exceeded that of
sputum smear microscopy, and there was an incremental yield
when these tests were used in combination. The sensitivity of
the LAM ELISA was highest among patients with the lowest CD4
cell counts (Figure 3). In ambulatory patients screened before
ART and in hospitalized HIV-infected patients with suspected
TB who had CD4 cell counts <50 cells/μL, the sensitivities of the assay were 67% and 85%, respectively [34, 64]. Very high specificity was observed in both studies. Greater sensitivity at lower CD4 cell counts is consistent with the fact that patients with markedly impaired antimycobacterial immune responses tend to have disseminated, multibacillary disease, and thus, the likelihood of mycobacterial antigenuria is likely to be increased.

A simplified lateral flow version of this assay (dip-stick) is currently being evaluated [65]. If the sensitivity and specificity of this is at least comparable to that of ELISA, it could be used as a simple and cheap point-of-care test incorporated in a diagnostic screening algorithm for outpatients accessing ART or for HIV-infected inpatients. This would reduce the mean time to TB diagnosis by ~3 weeks in approximately half the patients with TB who had CD4 cell counts <100 cells/μL in a South African ART program [34].

**Nucleic Acid Amplification Tests (NAATs)**

NAATs represent the most promising development for rapid diagnosis of TB and rapid drug-susceptibility testing [68]. However, their technical complexity has hindered widespread implementation in resource-limited settings. Moreover, their usefulness when applied directly to smear-negative sputum samples has been limited to date. However, considerable progress has been made in developing simplified versions with higher sensitivity for smear-negative disease. A manual NAAT using loop-mediated isothermal amplification with a simple visual colorimetric read-out showed high specificity but only moderate sensitivity for smear-negative culture-positive disease [69]. A revised prototype is undergoing further evaluation in peripheral laboratory facilities in resource-constrained settings.

The most important development to date is a sensitive and specific fully automated and commercially available NAAT assay, which has been developed for use outside reference laboratory centers [70, 71]. The Xpert MTB/RIF assay (Cepheid) uses a series of molecular beacons and real-time polymerase chain reaction technology to detect *M. tuberculosis* and the *rpoB* rifampicin resistance mutation. The cartridge-based system dispenses with the need for prior sputum processing and requires minimal laboratory expertise; furthermore, results are available <2 hours, permitting a specific TB diagnosis and rapid detection of rifampicin resistance. A large multicountry evaluation found excellent performance characteristics, including sensitivities of 72.5%, 85.1%, and 90.2% for sputum smear-negative disease when processing 1, 2, or 3 sputum specimens, respectively [71].

However, when used to screen for TB in patients starting ART, the Xpert MTB/RIF assay may be stretched to its limits of detection [62]. Laboratory evaluations have shown a limit of detection (as defined by 95% sensitivity) of 131 bacilli per mL of sputum [70], whereas automated liquid culture systems have a sensitivity range of 10–100 organisms per mL. It will be important to assess the sensitivity of the Xpert MTB/RIF assay among patients commencing ART in whom bacillary numbers in sputum are often very low. Multiple samples may be needed to achieve adequate sensitivity, which will increase costs. However, the simplicity of use of this technology means that the machines could be located at ART clinics and used by health care personnel after minimal training. Such field evaluations of this technology are ongoing.

**Interferon-γ Release Assays**

Interferon-γ release assays detect interferon-γ production from peripheral blood mononuclear cells after in vitro stimulation with antigens, such as ESAT-6 and CFP-10 (immunodominant antigens expressed by members of the *M. tuberculosis* complex) [72]. These assays have a sensitivity of 80%–90% among patients with confirmed TB but are unable to distinguish between active and latent disease, resulting in very poor specificity as a TB diagnostic in populations in settings with a high TB burden where prevalence of latent infection is high. These assays therefore have no role for TB diagnosis in resource-limited settings.

**Rapid Detection of Drug-Resistant TB**

The global emergence of the MDR-TB epidemic provides a particular threat to patients in ART services [11], as evidenced by the devastating outbreak of XDR-TB in rural KwaZulu Natal, South Africa, during 2005–2006 [48]. The outbreak was believed to have been caused by nosocomial transmission in patients

![Figure 3. Sensitivity of a commercially available enzyme-linked immunosorbent assay (ELISA) to detect lipoarabinomannan (LAM) in urine samples for diagnosis of tuberculosis (TB) in a cohort of patients accessing antiretroviral treatment (ART) in a South African township. The sensitivity of sputum microscopy and the LAM ELISA are shown individually and combined (either positive), compared with a gold standard of automated liquid culture of 2 sputum samples. Data are stratified by CD4 cell count. Data are from Lawn et al (2009) [34].](image-url)
accessing ART at a district hospital. Expanded capacity for TB screening and rapid phenotypic or genotypic resistance testing is urgently needed.

To enhance capacity for rapid diagnosis of MDR-TB, in 2008, the WHO approved use of line probe assays for the rapid molecular detection of drug resistance in smear-positive specimens or culture isolates [73, 74]. Two commercial line probe assays have shown high accuracy when applied to culture isolates, and one of these, the GenoType MTBDRplus assay (Hain Lifescience GmbH), has also shown very good performance characteristics when applied directly to smear-positive sputum specimens [75, 76].

In 2009, the GenoType MTBDRsl assay (Hain Lifescience GmbH) became available; it is also able to detect resistance to fluoroquinolones, aminoglycosides, and ethambutol in culture isolates or smear-positive sputum specimens [77]. When used together with the GenoType MTBDRplus assay (which detects resistance to rifampicin and isoniazid), the combined results potentially provide a means of rapid detection of XDR-TB. Use of such molecular assays reduces the time to diagnosis of MDR-TB and XDR-TB from weeks or months to days. However, line probe assays are technically demanding and require complex infrastructure and highly trained staff; thus, their use is limited to centralized laboratories. Their impact on patient outcomes has yet to be demonstrated. Simplified automated NAATs, such as the Xpert MTB/RIF assay, may provide a simpler means for rapid detection of drug resistance.

**CONCLUSIONS**

TB represents a huge challenge to ART services in resource-limited settings, and this requires the implementation of routine, systematic, and effective screening. Progress has been made in developing a better screening algorithm, and there is a developmental pipeline of very promising new diagnostic technologies that require evaluation in this specific patient population. Newer culture-based systems, simplified NAATs, and urinary antigen detection may each play an important role, depending on the setting, local laboratory capacity, and human resources available. Implementation of these new tools is vital to permit rapid and effective screening for TB in ART services, which must be regarded as an essential component of patient care.

**Notes**

*Acknowledgements.* This article was published as part of the TB diagnostics supplement sponsored by the KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH), the Harvard University Center for AIDS Research (CFAR), the Albert Einstein College of Medicine, and the Einstein-Montefiore CFAR (Center for AIDS Research).

*Financial Support.* This work was funded by Wellcome Trust (to S. D. L.) and the Division of AIDS of the National Institute of Allergy and Infectious Disease, the National Institutes of Health (CIPRA grant 1U19AI53217-01 and ROI grant AI058736-01A1 to R. W.).

*Potential conflicts of interest.* All authors: no reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

**References**

1. Lawn SD, Churchyard G. Epidemiology of HIV-associated tuberculosis. *Carr Opin HIV AIDS* 2009; 4:325–33.
2. World Health Organization. Global tuberculosis control. A short update to the 2009 report. Geneva: WHO, 2009. [http://www.who.int/tb/publications/global_report/2009/update/tbu_9.pdf](http://www.who.int/tb/publications/global_report/2009/update/tbu_9.pdf). Accessed 1 March 2010.
3. WHO/UNAIDS/UNICEF. Towards universal access. Scaling up priority HIV/AIDS interventions in the health sector. Geneva: WHO, 2010. [http://www.who.int/hiv/pub/2010progressreport/summary_en.pdf](http://www.who.int/hiv/pub/2010progressreport/summary_en.pdf). Accessed 4 October 2010.
4. Harries AD, Zachariah R, Lawn SD. Providing HIV care for coinfected tuberculosis patients: a perspective from sub-Saharan Africa. *Int J Tuberc Lung Dis* 2009; 13:6–16.
5. Lawn SD, Kranzer K, Wood R. Antiretroviral therapy for control of the HIV-associated tuberculosis epidemic in resource-limited settings. *Clin Chest Med* 2009; 30:685–99.
6. Golub JE, Durovni B, King BS, et al. Recurrent tuberculosis in HIV-infected patients in Rio de Janeiro, Brazil. *AIDS* 2008; 22:2527–33.
7. Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ, Churchyard GI. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. *Lancet Infect Dis* 2010; 10:489–98.
8. Lawn SD, Harries AD, Williams BG, et al. Will ART do it? Antiretroviral therapy and the control of HIV-associated tuberculosis. *Int J Tuberc Lung Dis* 2010; 15:571–81.
9. McIlheron H, Meintjes G, Burman WJ, Maartens G. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome. *J Infect Dis* 2007; 196(Suppl 1):S63–575.
10. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. *Lancet Infect Dis* 2005; 5:361–73.
11. Bock NN, Jensen PA, Miller B, Nardell E. Tuberculosis infection control in resource-limited settings in the era of expanding HIV care and treatment. *J Infect Dis* 2007; 196(Suppl 1):S108–S113.
12. Lawn SD, Butera ST, Shinnick TM. Tuberculosis unleashed: the impact of human immunodeficiency virus infection on the host granulomatous response to Mycobacterium tuberculosis. *Microbes Infect* 2002; 4:635–46.
13. Sonnenberg P, Glynn JR, Fielding K, et al. How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. *J Infect Dis* 2005; 191:150–8.
14. Holmes CB, Wood R, Badri M, et al. CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. *J Acquir Immune Defic Syndr* 2006; 42:464–9.
15. Lawn SD, Myer L, Edwards D, Bekker LG, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. *AIDS* 2009; 23:1717–25.
16. Antonucci G, Girardi E, Raviglione MC, Ippolito G. Risk factors for tuberculosis in HIV-infected persons. A prospective cohort study. The Gruppo Italiano di Studio Tuberculosis e AIDS (GISTA). *JAMA* 1995; 274:143–8.
17. Corbett EL, Watt CJ, Walker N, et al. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. *Arch Intern Med* 2003; 163:1009–21.
18. Lawn SD, Wood R, Wilkinson RJ. Changing concepts of latent tuberculosis infection in patients living with HIV infection. *Clin Devel Immunol* 2010; doi: 10.1155/2011/980594.
19. Young DB, Gideon HP, Wilkinson RJ. Eliminating latent tuberculosis. Trends Microbiol 2009; 17:183–8.

20. Barry CE III, Boshoff HJ, Dartois V, et al. The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 2009; 7:845–55.

21. Gillis CF, Brindle RJ, Otieno LS, et al. Extrapulmonary and disseminated tuberculosis in HIV-1-seropositive patients presenting to the acute medical services in Nairobi. AIDS 1990; 4:981–5.

22. Elliott AM, Hlawiindi B, Hayes RJ, et al. The impact of human immunodeficiency virus on presentation and diagnosis of tuberculosis in a cohort study in Zambia. J Trop Med Hyg 1993; 96:1–11.

23. Lucas SB, De Cock KM, Hounnou A, et al. Contribution of tuberculosis to slim disease in Africa. BMJ 1994; 308:1531–3.

24. Rana F, Hawken MP, Meme HK, et al. Autopsy findings in HIV-1-infected adults in Kenya. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14:83–5.

25. Lawn SD, Evans AJ, Sedgwick PM, Acheampong JW. Pulmonary tuberculosis: radiological features in West Africans infected with HIV. Br J Radiol 1999; 72:339–44.

26. Post FA, Wood R, Pillay GP. Pulmonary tuberculosis in HIV infection: radiographic appearance is related to CD4+ T-lymphocyte count. Tuberc Lung Dis 1995; 76:18–21.

27. Getahun H, Harrington M, O’Brien R, Nunn P. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resource-constrained settings: informing urgent policy changes. Lancet 2007; 369:2042–9.

28. Lawn SD, Harries AD, Anglard X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22:1897–908.

29. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20:1605–12.

30. Lawn SD, Fraenzel A, Kranzer K, et al. Provider initiated HIV testing increases access of patients with HIV-associated tuberculosis to antiretroviral therapy. S Afr Med J 2010; 101:258–62.

31. Kranzer K, Houben RM, Glynn JR, Bekker LG, Wood R, Lawn SD. Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:93–102.

32. Reid MJ, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis 2009; 9:173–84.

33. Bassett IV, Wang B, Chetty S, et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis 2010; 51:823–9.

34. Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker LG, Wood R. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS 2009; 23:1875–80.

35. Cain KP, McCarthy KD, Heilig CM, et al. An algorithm for tuberculosis screening and diagnosis in people with HIV. N Engl J Med 2010; 362:707–10.

36. Monkongdee P, McCarthy KD, Cain KP, et al. Yield of acid-fast smear and mycobacterial culture for tuberculosis diagnosis in people with human immunodeficiency virus. Am J Respir Crit Care Med 2009; 180:903–8.

37. Chheng P, Tamhane A, Natpratan C, et al. Pulmonary tuberculosis among patients visiting a voluntary confidential counseling and testing center, Cambodia. Int J Tuberc Lung Dis 2008; 12(3 Suppl 1):54–62.

38. Lawn SD, Kranzer K, Edwards DJ, McNally M, Bekker LG, Wood R. Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS 2010; 24:1323–8.

39. Lawn SD, Wilkinson RJ, Lipman MC, Wood R. Immune reconstitution and “unmasking” of tuberculosis during antiretroviral therapy. Am J Respir Crit Care Med 2008; 177:680–5.
60. Dawson R, Masuka P, Edwards DJ, et al. Chest radiograph reading and recording system: evaluation for tuberculosis screening in patients with advanced HIV. Int J Tuberc Lung Dis 2010; 14:52–8.

61. World Health Organization. The use of liquid TB culture and drug susceptibility testing (DST) in low and medium income settings. Geneva: WHO, 2007. http://www.who.int/tb/dots/laboratory/Use%20of%20Liquid%20TB%20Culture_Summary%20Report.pdf. Accessed 5 January 2010.

62. Lawn SD, Wood R. Tuberculosis screening in patients starting antiretroviral therapy: stretching diagnostics to the limits. Clin Infect Dis 2011; 52:276–77.

63. Moore DA, Evans CA, Gilman RH, et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 2006; 355:1539–50.

64. Steingart KR, Henry M, Laal S, et al. Commercial serological antibody detection tests for the diagnosis of pulmonary tuberculosis: a systematic review. PLoS Med 2007; 4:e202.

65. Peter J, Green C, Hoelscher M, Mwaba P, Zdaha K. Urine for the diagnosis of tuberculosis: current approaches, clinical applicability, and new developments. Curr Opin Pulm Med 2010; 16:262–70.

66. Shah M, Variava E, Holmes CB, et al. Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a high HIV prevalence setting. J Acquir Immune Defic Syndr 2009; 52:145–51.

67. Dheda K, Davids V, Lenders L, et al. Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples. PLoS One 2010; 5:e9848.

68. Pai M, Minion J, Sohn H, Zwerling A, Perkins MD. Novel and improved technologies for tuberculosis diagnosis: progress and challenges. Clin Chest Med 2009; 30:701–16.

69. Boehme CC, Nabeta P, Henostroza G, et al. Operational feasibility of using loop-mediated isothermal amplification for diagnosis of pulmonary tuberculosis in microscopy centers of developing countries. J Clin Microbiol 2007; 45:1936–40.

70. Helb D, Jones M, Story E, et al. Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol 2010; 48:229–37.

71. Boehme CC, Nabeta P, Hillemann D, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363:1005–15.

72. Pai M, Zwerling A, Menzies D. Systematic review: T cell–based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med 2008; 149:177–84.

73. World Health Organization. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Policy statement June 2008. Geneva: WHO, 2008. http://www.who.int/tb/features_archive/policy_statement.pdf. Accessed 22 July 2011.

74. Barnard M, Albert H, Coetzee G, O’Brien R, Bosman ME. Rapid molecular screening for multidrug-resistant tuberculosis in a high-volume public health laboratory in South Africa. Am J Respir Crit Care Med 2008; 177:787–92.

75. Morgan M, Kahantri S, Flores L, Pai M. A commercial line probe assay for the rapid detection of rifampicin resistance in Mycobacterium tuberculosis: a systematic review and meta-analysis. BMC Infect Dis 2005; 5:62.

76. Ling DI, Zwerling AA, Pai M. GenoType MTBDR assays for the diagnosis of multidrug-resistant tuberculosis: a meta-analysis. Eur Respir J 2008; 32:1165–74.

77. Hillemann D, Rusch-Gerdes S, Richter E. Feasibility of the GenoType MTBDRsl assay for fluoroquinolone, amikacin-capreomycin, and ethambutol resistance testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2009; 47:1767–72.